Study summary

Adding ivonescimab to chemotherapy modestly extended survival after EGFR pills

HARMONi-A trial (ivonescimab) · 322 people, phase 3 · Published July 2026, JAMA

16.8months median survival, vs 14.1 with chemotherapy alone

What was tested

Ivonescimab, an antibody that blocks both PD-1 and VEGF, or placebo, added to chemotherapy after EGFR pills stopped working. Run in China.

What they found

What it means

A possible option after resistance; regulators will weigh the global trial.

JAMA, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.